Using ECG and echocardiography markers to predict pulmonary hypertension
Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography
This project will test whether new ECG and echocardiogram measurements of right heart function can help detect pulmonary hypertension in adults who have had these tests and right heart catheterisation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal United Hospitals Bath NHS Foundation Trust Academic / other |
| Locations | 5 sites (Bath, Banes and 4 other locations) |
| Trial ID | NCT06386185 on ClinicalTrials.gov |
What this trial studies
This is an observational, multicentre project using clinical data from adults who underwent transthoracic echocardiography (TTE), electrocardiography (ECG) and right heart catheterisation (RHC) during routine care. Investigators will extract novel markers of right ventricular function from ECG and echo recordings and build a probability algorithm to flag likely pulmonary hypertension. The algorithm's performance will be compared with current screening guidelines and validated across participating UK centres. No experimental treatments are given; the work analyses existing clinical measurements to try to improve detection.
Who should consider this trial
Good fit: Adults aged 18 or older who have undergone TTE, ECG and RHC as part of their clinical care at the participating centres and who have not opted out of research use of their data.
Not a fit: Children, people with known or suspected congenital heart disease, anyone who lacks one or more of the required tests, or those who have opted out of data sharing are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this could enable earlier and more accurate detection of pulmonary hypertension so patients can start life‑saving treatments sooner.
How similar studies have performed: Some prior studies have identified ECG and echo features that suggest PH, but combining novel right ventricular markers into a validated probability algorithm is relatively new and not yet widely proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18+ who have undergone TTE, ECG and RHC as part of their clinical care Exclusion Criteria: * Patients \<18 years old * Known or suspected congenital heart disease * Patient has opted-out of allowing their data to be used for research and planning (via the national data opt-out choice in England, or equivalent data protection scheme in Scotland)
Where this trial is running
Bath, Banes and 4 other locations
- Royal United Hospital NHS Foundation Trust — Bath, Banes, United Kingdom (Recruiting)
- Golden Jubilee Hospital — Glasgow, Lanarkshire, United Kingdom (Not_yet_recruiting)
- Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield, South Yorkshire, United Kingdom (Not_yet_recruiting)
- Royal Papworth Hospital — Cambridge, United Kingdom (Not_yet_recruiting)
- Royal Free NHS Foundation Trust — London, United Kingdom (Not_yet_recruiting)
Study contacts
- Principal investigator: Daniel X Augustine — Royal United Hospital
- Study coordinator: Christopher Wild
- Email: chris.wild1@nhs.net
- Phone: +4407891662866
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.